Recent Finacing
Recent Raise
Faron Pharmaceuticals develops bexmarilimab, an anti-Clever-1 antibody to reprogram myeloid cells for anti-tumor immunity, conducting Phase II BEXMAB trials with azacitidine and pursuing regulatory submissions.
Focus Areas
Total Raised
Funding round
See the team members at Faron Pharmaceuticals.
